ciprofloxacin has been researched along with sparfloxacin in 209 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.48) | 18.7374 |
| 1990's | 123 (58.85) | 18.2507 |
| 2000's | 63 (30.14) | 29.6817 |
| 2010's | 20 (9.57) | 24.3611 |
| 2020's | 2 (0.96) | 2.80 |
| Authors | Studies |
|---|---|
| Bridges, AJ; Culbertson, TP; Domagala, JM; Gambino, L; Hagen, SE; Karrick, G; Porter, K; Sanchez, JP; Sesnie, JA; Spense, FG | 1 |
| Chiba, K; Egawa, H; Fujita, M; Kataoka, M; Matsumoto, J; Minamida, A; Miyamoto, T; Nishimura, Y; Okada, H; Shibamori, K | 1 |
| Cohen, MA; Domagala, JM; Gogliotti, RD; Gracheck, SJ; Huband, MD; Sanchez, JP; Sesnie, JA; Shapiro, MA | 1 |
| Dever, JA; Domagala, JM; Gracheck, SJ; Renau, TE; Sanchez, JP; Shapiro, MA | 1 |
| Dever, JA; Domagala, JM; Gage, JW; Gracheck, SJ; Renau, TE; Sanchez, JP; Shapiro, MA | 1 |
| Carrupt, PA; Crivori, P; Cruciani, G; Testa, B | 1 |
| Keserü, GM | 1 |
| Baroni, M; Cecchetti, V; Cianchetta, G; Cruciani, G; Mannhold, R | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Appelbaum, PC; Bhawsar, SB; Bozdogan, B; de Souza, NJ; Desai, VN; Deshpande, PK; Gupte, SV; Hooper, DC; Jacobs, MR; Jha, R; Khorakiwala, HF; Patel, MV; Shetty, N; Shukla, MC; Strahilevitz, J; Yeole, RD | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bachand, B; Barnes, MH; Bethell, R; Brown, NC; Butler, MM; Cadilhac, C; Charron, S; Comstock, J; Dix, EJ; Foster, KA; Holm, KA; LaMarr, WA; Lamothe, S; Long, ZY; Manikowski, A; Motorina, I; Storer, R; Tarantino, PM; Wright, GE; Xu, WC; Zhi, C | 1 |
| Arpin, C; Ba, BB; Caignard, DH; Forfar-Bares, I; Grellet, J; Guillon, J; Jarry, C; Moreau, S; Quentin, C; Vidaillac, C | 1 |
| Balasubramanian, V; Bharath, S; Gaonkar, S; Jayaram, R; Jayashree, R; Kaur, P; Mahesh, BN; Nandi, V; Shandil, RK; Suresh, BL | 1 |
| Jain, M; Jayadev, S; Mishra, B; Patel, PR; Solanki, M; Soni, R; Srivastava, BK; Valani, D | 1 |
| Aubry, A; Cambau, E; Jarlier, V; Matrat, S; Petrella, S; Sougakoff, W | 1 |
| Allison, BD; Goldschmidt, RM; Gomez, L; Grice, CA; Hack, MD; Jones, TK; Morrow, BJ; Motley, ST; Santillán, A; Schwarz, KL; Shaw, KJ; Shinde, S; Tang, L; Venkatesan, H; Wiener, JJ | 1 |
| Cattoir, V; Mazel, D; Nordmann, P; Poirel, L; Soussy, CJ | 1 |
| Cattoir, V; Nordmann, P; Poirel, L | 1 |
| Arakawa, Y; Kato, H; Kimura, K; Konda, T; Shibata, N; Shibayama, K; Suzuki, S; Wachino, J; Yamane, K | 1 |
| Arsène, S; Leclercq, R | 1 |
| Morgan-Linnell, SK; Zechiedrich, L | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Jia, L; Sun, H | 1 |
| Cattoir, V; Espinal, P; Nordmann, P; Poirel, L; Silva-Sanchez, J | 1 |
| Hiramatsu, K; Kikuchi, K; Ohtsuka, M; Ono, Y; Sasaki, T; Shimizu, K; Takahashi, N | 2 |
| Bremont, S; Charavay, F; Courvalin, P; Goarant, C; Le Hello, S; O'Connor, O; Page, S; Vernel-Pauillac, F | 1 |
| Cui, L; Hiramatsu, K; Neoh, HM; Shoji, M | 1 |
| Baliani, A; Barrett, MP; Chollet, C; Gilbert, IH; Wong, PE | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chhasatia, MR; Gandhi, DS; Patel, MN | 1 |
| Azéma, J; Dewelle, J; Guidetti, B; Kiss, R; Korolyov, A; Le Calve, B; Malet-Martino, M; Martino, R; Mijatovic, T; Vaysse, J | 1 |
| Avdeef, A; Sun, N; Tam, KY; Tsinman, O | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Blango, MG; Mulvey, MA | 1 |
| Avdeef, A; Tam, KY | 1 |
| Gotoh, N; Hayashi, N; Okuda, J; Wakahara, Y | 1 |
| Gozalbes, R; Pineda-Lucena, A | 1 |
| Anderson, BE; Burda, WN; Cormier, R; Edlinger, J; Harrington, L; Kapolka, R; Kodigepalli, KM; Roma, G; Shaw, LN; Thomas, J; Turos, E | 1 |
| Imai, YN; Oiki, S; Ryu, S | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Akylbekov, N; Bulatova, A; Burilov, A; Chugunova, E; Dobrynin, A; Gavrilov, N; Kulik, N; Syakaev, V; Voloshina, A; Zobov, V | 1 |
| Cheng, XW; Fan, YL; Feng, LS; Wu, JB; Zhang, FZ | 1 |
| Zhang, B | 1 |
| Ciura, K; Fallarero, A; Fedorowicz, J; Gilbert-Girard, S; Konopacka, A; Lejnowski, D; Morawska, M; Sączewski, J; Savijoki, K; Skok, Ž; Tomašič, T; Waleron, K | 1 |
| Blaskovich, MAT; Pham, TDM; Ziora, ZM | 1 |
| Armstrong, D; Balibar, CJ; Bauer, D; Bellamacina, C; Benton, BM; Bussiere, D; De Pascale, G; De Vicente, J; Dean, CR; Dhumale, B; Fisher, LM; Fuller, J; Fulsunder, M; Holder, LM; Hu, C; Kantariya, B; Lapointe, G; Leeds, JA; Li, X; Lu, P; Lvov, A; Ma, S; Madhavan, S; Malekar, S; McKenney, D; Mergo, W; Metzger, L; Moser, HE; Mutnick, D; Noeske, J; Osborne, C; Patel, A; Patel, D; Patel, T; Prajapati, K; Prosen, KR; Reck, F; Richie, DL; Rico, A; Rivkin, A; Sanderson, MR; Satasia, S; Sawyer, WS; Selvarajah, J; Shah, N; Shanghavi, K; Shu, W; Skepper, CK; Thompson, KV; Traebert, M; Vala, A; Vala, L; Veselkov, DA; Vo, J; Wang, M; Widya, M; Williams, SL; Xu, Y; Yue, Q; Zang, R; Zhou, B | 1 |
| Betson, M; Bingham, M; Doyle, P; Hallworth, S; Harvey, R; Huxley, A; Kirk, R; Moat, J; Nelson, G; Pesnot, T; Tait, M | 1 |
| Cobbs, CG; Smith, KR | 1 |
| Almodovar, E; Burns, JJ; Qadri, SM; Rabea, N; Ueno, Y | 1 |
| Akaniro, JC; Arguedas, AG; Stutman, HR; Vargas, OM | 1 |
| Feistauer, SM; Georgopoulos, A; Georgopoulos, M; Graninger, W; Pfleger, S | 1 |
| Bergogne-Bérézin, E; Joly-Guillou, ML | 1 |
| Hammerschlag, MR; Hyman, CL; Roblin, PM | 1 |
| Morrissey, I; Smith, JT | 1 |
| Appelbaum, PC; Jacobs, MR; Spangler, SK | 2 |
| Citron, DM; Goldstein, EJ | 1 |
| Azoulay-Dupuis, E; Bauchet, J; Bedos, JP; Pocidalo, JJ; Vallee, E; Veber, B | 1 |
| Bouzard, D; Di Cesare, P; Fung-Tomc, J; Hoffmann, P; Kessler, R | 1 |
| Forstall, GJ; Knapp, CC; Washington, JA | 1 |
| Andrews, JM; Cooper, MA; Wise, R | 1 |
| Azoulay-Dupuis, E; Bergogne-Bérézin, E; Pocidalo, JJ; Vallée, E | 1 |
| Baltch, AL; Louie, A; Ritz, WJ; Smith, RP | 1 |
| Nishino, T; Okamoto, S; Okuda, J; Takahata, M | 1 |
| Piddock, LJ; Zhu, M | 1 |
| Barry, AL; Fuchs, PC | 2 |
| Cassell, GH; Crabb, D; Duffy, LB; Pate, MS; Schmid, T; Waites, KB | 1 |
| Goh, KS; Rastogi, N | 1 |
| Chin, NX; Gu, JW; Neu, HC; Yu, KW; Zhang, YX | 1 |
| Kayser, FH; Wüst, J | 1 |
| Allen, SD; Barry, AL; Fuchs, PC; Gerlach, EH; Pfaller, MA | 1 |
| Dorr, MB; Edelstein, MA; Edelstein, PH; Weidenfeld, J | 1 |
| Andrews, JM; Ashby, JP; Cooper, MA; Matthews, RS; Wise, R | 1 |
| Hadley, WK; Nassos, PS; Sanders, CA; Yajko, DM | 1 |
| Bale, MJ; Doebbeling, BN; Pfaller, MA; Wenzel, RP | 1 |
| Bodey, GP; Ho, DH; LeBlanc, B; Messer, M; Nguyen, H; Rolston, KV | 1 |
| Chaudhry, AZ; Knapp, CC; Sierra-Madero, J; Washington, JA | 1 |
| Hashimoto, M; Kurobe, N; Nakamura, S; Ohue, T; Shimizu, M | 1 |
| Kashimoto, S; Kojima, T; Kouno, K; Kurobe, N; Minami, A; Nakamura, S; Nakata, K; Ohue, T; Sakaguchi, Y; Yoshida, H | 1 |
| Cagni, A; Chuard, C; Lew, DP; Schrenzel, J; Vaudaux, PE | 1 |
| Khac, SB; Moreau, NJ | 1 |
| Gensberg, K; Jin, YF; Piddock, LJ | 1 |
| Bauernfeind, A | 1 |
| Carbon, C; Dautrey, S; Farinoti, R; Ramon, J; Rubinstein, E; St Julien, L | 1 |
| Jones, RN; Sutton, LD | 1 |
| Cantón, E; Pastor, A; Pemán, J | 2 |
| Kaatz, GW; Larsson, AJ; Moody, JA; Rotschafer, JC; Walker, KJ; Zabinski, RA | 1 |
| Avril, JL; Donnio, PY; Gastine, C; Travert, MF | 1 |
| Cooper, B; Freeman, C; Mazens-Sullivan, M; Nightingale, C; Quintiliani, R; Robinson, A | 1 |
| Cormican, MG; Jones, RN; Marshall, SA | 1 |
| Appelbaum, PC; Jacobs, MR; Pankuch, GA | 1 |
| Aoki, M; Goldstein, E; Kunii, O; Ono, Y | 1 |
| Cid, D; de la Fuente, R; Garcia, S; Piriz, S; Ruiz-Santa-Quiteria, JA; Vadillo, S; Valle, J | 1 |
| el-Kersh, TA; Ramadan, MA; Shibl, AM; Tawfik, AF | 1 |
| Anderson, MR; Brighty, KE; Castaldi, MJ; Gootz, TD; Haskell, SL; McGuirk, PR; Schmieder, BJ; Sutcliffe, JA | 1 |
| Cherubin, CE; Stratton, CW | 1 |
| Chin, NX; Neu, HC | 1 |
| Fresnadillo, MJ; García García, MI; García Sánchez, E; García Sánchez, JE; García-Rodríguez, JA; Trujillano, I | 1 |
| Aldridge, KE | 1 |
| Blanco, MT; Gómez-García, AC; Hurtado, C; Morán, FJ; Pérez-Giraldo, C; Rodríguez-Benito, A | 1 |
| Charter, M; Davey, PG; Freeman, A; Jacobson, I; Kelly, S; Lambert, J; Precious, E; Varma, TR | 1 |
| Martínez-Martínez, L; Ortega, MC; Perea, EJ; Suárez, AI | 1 |
| Borobio, MV; Conejo, M; Perea, EJ; Ramirez, E; Suarez, AI | 1 |
| Phillips, I; Power, EG | 1 |
| Croizé, J; Le Noc, D; Le Noc, P | 1 |
| Ahlén, S; Malmborg, AS | 1 |
| Andrews, JM; Brenwald, N; Wise, R | 1 |
| Mitsuhashi, S; Yoshida, T | 1 |
| Beumer, H; Hoepelman, AI; Rozenberg-Arska, M; Verhoef, J; Visser, MR | 1 |
| Brumfitt, W; Hamilton-Miller, JM | 1 |
| Amsterdam, D; Beam, TR; Gorzynski, EA; Mandell, LA; Rotstein, C | 1 |
| Dalhoff, A | 1 |
| Berche, P; Gaillot, O | 1 |
| Barlow, D; Gianotti, B; Jean, C; Moi, H; Morel, P; Phillips, I | 2 |
| Asaoka, T; Imamori, K; Maebashi, K; Matsuda, H; Matsumoto, M; Tahara, Y | 1 |
| Appelbaum, PC; Jacobs, MR; Visalli, MA | 1 |
| Iakovlev, SV; Iakovlev, VP; Izotova, GN | 1 |
| Ibuki, E; Masuda, N; Miyoshi, H; Nishino, T; Otsuki, M; Takahashi, Y | 1 |
| di Silverio, F; Geddes, A; Guibert, J; Naber, KG | 1 |
| Chilima, BZ; Okazawa, Y; Tanno, K; Tosaka, M; Yamane, N | 1 |
| Hayakawa, I; Hohmura, M; Hoshino, K; Ishida, H; Kitamura, A; Nishino, T; Sato, K; Tanaka, M | 1 |
| Chambers, HF; Hackbarth, CJ; Kocagöz, T; Nikaido, H; Rosenberg, EY; Unsal, I | 1 |
| Aoun, M; Crokaert, F; Duchateau, V; Grenier, P; Klastersky, J; Vandermies, A | 1 |
| Breilh, D; Celerier, C; Dorian, M; Grellet, J; Leng, B; Pellegrin, JL; Rispal, P; Saux, MC | 1 |
| Conejo, MC; García, I; Pascual, A; Perea, EJ; Salvador, J | 1 |
| Bergogne-Bérézin, E; Houot, S; Joly-Guillou, ML; Moreau, NJ | 1 |
| Davies, BI; Dirks-Go, SI; Hoogkamp-Korstanje, JA; Kabel, P; Manson, WL; Stobberingh, EE; Vreede, RW | 1 |
| Fabian, I; Gruss, T; Kletter, Y; Shalit, I; Weiss, K | 1 |
| Gutmann, L; Janoir, C; Kitzis, MD; Moreau, NJ; Zeller, V | 1 |
| Andrews, JM; Boswell, F; Brenwald, NP; Wise, R | 1 |
| Choi, EC; Choi, KH; Hong, JS; Kim, SK; Lee, DK; Yoon, SJ | 1 |
| Barry, AL; Brown, SD; Fuchs, PC | 1 |
| Citron, DM; Goldstein, EJ; Hudspeth, M; Hunt Gerardo, S; Merriam, CV | 1 |
| Borner, K; Koeppe, P; Lode, H; Schaberg, T; Schüler, P; Zemper, K | 1 |
| George, J; Morrissey, I | 1 |
| Dvorak, T; Ho, DH; LeBlanc, B; Rolston, KV; Streeter, H | 1 |
| Hoogkamp-Korstanje, JA | 1 |
| Dasgupta, MK; Larabie, M; Micetich, RG; Salama, S; Shishido, H; Singh, R | 1 |
| Jones, RN; Pfaller, MA | 1 |
| Choi, EC; Choi, KH; Kim, BK; Kim, JH; Kim, JW; Lee, JH | 1 |
| Hoban, DJ; Karlowsky, JA; Zhanel, GG | 1 |
| Azoulay-Dupuis, E; Bédos, JP; Moine, P; Muffat-Joly, M; Pocidalo, JJ; Vallée, E; Veber, B | 1 |
| Baumann-Wilschke, I; Förster, C; Rücker, M; Shakibaei, M; Stahlmann, R; Vormann, J | 1 |
| Dorian, M; Grellet, J; Saux, MC | 1 |
| Beach, ML; Doern, GV; Jones, RN; Pfaller, MA | 1 |
| Biavasco, F; Mingoia, M; Montanari, MP; Prenna, M; Ripa, S; Varaldo, PE | 1 |
| Heisig, P; Jones, ME; Klootwijk, M; Schmitz, FJ; Verhoef, J; Visser, MR | 1 |
| Kamberi, M; Kawano, K; Kotegawa, T; Nakamura, K; Nakano, S; Niki, Y; Tsutsumi, K | 1 |
| Engler, B; Fluit, AC; Hadding, U; Heinz, HP; Hofmann, B; Jones, ME; Lückefahr, M; Schmitz, FJ; Verhoef, J | 1 |
| Espasa, M; Gómez-Martínez, J; Jiménez de Anta, MT; Marco, F; Martínez, JA; Mensa, J | 1 |
| Dabernat, H | 1 |
| Fisher, LM; Pan, XS | 1 |
| Henry, DC; Lipsky, BA; Magner, DJ; McCabe, A; Miller, B; Nolan, T; Schwartz, R; Talbot, GH | 1 |
| Appelbaum, PC; Hoellman, DB; Jacobs, MR; Lin, G | 1 |
| Bébéar, C; Bébéar, CM; Leblanc, F; Renaudin, H; Schaeverbeke, T | 1 |
| Frémaux, A; Geslin, P; Sissia, G | 1 |
| Acar, JF; Goldstein, FW; Kitzis, MD; Miegi, M | 1 |
| Bryskier, A; Drugeon, HB; Juvin, ME | 1 |
| Gootz, TD; Haskell, SL; Kaczmarek, FS; Maurice, AE; Zaniewski, RP | 1 |
| Beyer, R; Cianciotto, NP; Noskin, GA; Pestova, E; Peterson, LR | 1 |
| Dorr, MB; Henry, DC; Iravani, A; Magner, DJ; Mansfield, DL; Nenad, RC; Talbot, GH; Tice, AD | 1 |
| Bint, AJ; Legg, JM | 1 |
| Marre, R; Trautmann, M | 1 |
| Akaki, T; Kajitani, H; Sato, K; Shishido, S; Tomioka, H | 1 |
| Hershberger, E; Rybak, MJ | 1 |
| Amsterdam, D; Hardy, D; Mandell, LA; Rotstein, C | 1 |
| Anderson, VE; Gootz, TD; Kaczmarek, FS; Osheroff, N; Zaniewski, RP | 1 |
| King, DE; Lilley, SH; Malone, R | 1 |
| Bebear, C; Bebear, CM; Charron, A; Gruson, D; Lefrancois, M; Renaudin, H | 1 |
| Kanayama, A; Kobayashi, I; Mochida, O; Naito, S; Saika, T; Tanaka, M; Tunoe, H | 1 |
| Fraser, S; Mair, D; Patmore, L; Templeton, A | 1 |
| Gootz, TD | 1 |
| Bouquet, S; Couet, W; de Boer, AG; de Lange, EC; Delon, A; Marchand, S; van den Berg, D; van der Sandt, IC | 1 |
| Hashido, H; Ishigo, S; Iwata, I; Matsubara, S; Matsukawa, Y; Mikamo, H; Sawamura, H; Suematsu, H; Tamaya, T | 1 |
| Everett, D; Gillespie, SH; Morrissey, I | 1 |
| Kawahara, S; Nagare, H; Tada, A | 1 |
| Edwards, DI; Thorburn, CE | 1 |
| Andrews, JM; Boswell, FJ; Wise, R | 1 |
| Drexler, HG; Meyer, C; Uphoff, CC | 1 |
| Blandino, G; Caccamo, F; Milazzo, I; Musumeci, R; Nicoletti, G; Speciale, A | 1 |
| Hayakawa, H; Kawamura, Y; Miyazaki, M; Nagasawa, M; Nakamura, S; Nojima, Y | 1 |
| Fukuda, H; Kawamura, Y | 1 |
| Katouno, Y; Kobayashi, Y; Sugita, K; Uchida, H | 1 |
| Bermejo, MV; Garrigues, TM; Merino, V; Montalar-Montero, M; Nalda-Molina, R; Rodríguez-Ibáñez, M | 1 |
| Li, JL; Ma, XC; Tu, ZH; Xin, J; Zhang, T | 2 |
| Ono, C; Tanaka, M | 1 |
| Harigae, H; Ishikawa, S; Kaku, M; Kanemitsu, K; Kunishima, H; Saga, T; Takemura, H | 1 |
| Bao, L; Long, Y; Wu, YH; Xie, YX; Zeng, XW; Zhang, HD; Zhao, MC | 1 |
| Murakawa, GJ; Sable, D | 1 |
| Dong, C; Feng, YL | 1 |
| Paramasivan, CN; Rahman, F; Sulochana, S | 1 |
| Blanchard, JS; Hegde, SS; Maxwell, A; Mitchenall, LA; Roderick, SL; Takiff, HE; Vetting, MW | 1 |
| Squire, SB; Vizel, AA; Ziganshina, LE | 1 |
| Chen, X; Hua, H; Ji, C; Lin, X; Liu, Y; Tang, S; Yue, Z | 1 |
| Jagielski, M; Piekarska, K | 1 |
| Gierczyński, R; Jagielski, M; Kochman, M; Piekarska, K; Ławrynowicz-Paciorek, M | 1 |
| Kim, J; Ohtani, H; Sawada, Y; Tsujimoto, M | 1 |
| Anupama, M; Murthy, PB; Seiler, JP | 1 |
| Fadeyi, A; Olajide, TG; Segun-Busari, S | 1 |
| Betlejewska-Kielak, K; Biernacka, J; Grudzień, M; Kłosińska-Szmurło, E; Mazurek, AP; Pluciński, FA | 1 |
| Chaiprasert, A; Disratthakit, A; Doi, N; Leechawengwongs, M; Prammananan, T; Thaipisuttikul, I; Tribuddharat, C | 1 |
| Carneiro, ZA; de Albuquerque, S; de Oliveira, LP; de Souza, MVN; Guerra, W; Lima, MF; Lopes, CD; Paixão, DA; Pavan, FR; Pivatto, M; Ribeiro, CM; Teixeira, LR | 1 |
6 review(s) available for ciprofloxacin and sparfloxacin
| Article | Year |
|---|---|
Fluoroquinolone derivatives and their anti-tubercular activities.
Topics: Animals; Antitubercular Agents; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship; Tuberculosis | 2018 |
Comprehensive review on the anti-bacterial activity of 1,2,3-triazole hybrids.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Dose-Response Relationship, Drug; Humans; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship; Triazoles | 2019 |
Quinolone antibiotics.
Topics: | 2019 |
[Pharmacokinetics of fluoroquinolones in patients with renal insufficiency].
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Humans; Ofloxacin; Pefloxacin; Quinolones; Renal Insufficiency | 1995 |
Quinolones in dermatology.
Topics: Anti-Infective Agents; Area Under Curve; Bacterial Infections; Biological Availability; Ciprofloxacin; Fluoroquinolones; Humans; Intestinal Absorption; Microbial Sensitivity Tests; Nalidixic Acid; Quinolones; Skin Diseases; Structure-Activity Relationship | 2004 |
Fluoroquinolones for treating tuberculosis.
Topics: Antitubercular Agents; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Ofloxacin; Randomized Controlled Trials as Topic; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2005 |
7 trial(s) available for ciprofloxacin and sparfloxacin
| Article | Year |
|---|---|
Efficacy and safety of single oral dose sparfloxacin vs ciprofloxacin in acute gonococcal urethritis in males. A multicentre international study.
Topics: Acute Disease; Adult; Anti-Infective Agents; Ciprofloxacin; Double-Blind Method; Fluoroquinolones; Gonorrhea; Humans; Male; Neisseria gonorrhoeae; Quinolones; Urethritis | 1995 |
Comparative efficacy and safety of single oral doses of sparfloxacin versus ciprofloxacin in the treatment of acute gonococcal urethritis in men.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Anti-Infective Agents; Ciprofloxacin; Double-Blind Method; Drug Administration Schedule; Fluoroquinolones; Gonorrhea; Humans; International Cooperation; Male; Middle Aged; Quinolones; Urethritis | 1996 |
Comparative efficacy of sparfloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection.
Topics: Adolescent; Adult; Anti-Infective Agents; Ciprofloxacin; Double-Blind Method; Escherichia coli Infections; Female; Fluoroquinolones; Humans; International Cooperation; Male; Middle Aged; Quinolones; Urinary Tract Infections | 1996 |
Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes.
Topics: Anti-Infective Agents; Blood; Bronchoalveolar Lavage Fluid; Ciprofloxacin; Epithelium; Female; Fluoroquinolones; Humans; Leukocytes, Mononuclear; Lung; Macrophages, Alveolar; Male; Microbial Sensitivity Tests; Quinolones | 1997 |
Influences of urinary pH on ciprofloxacin pharmacokinetics in humans and antimicrobial activity in vitro versus those of sparfloxacin.
Topics: Adult; Anti-Infective Agents; Area Under Curve; Calcium; Chromatography, Gas; Ciprofloxacin; Culture Media; Escherichia coli; Fluoroquinolones; Half-Life; Humans; Hydrogen-Ion Concentration; Magnesium; Male; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 1999 |
Sparfloxacin versus ciprofloxacin for the treatment of community-acquired, complicated skin and skin-structure infections.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Community-Acquired Infections; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Skin Diseases, Infectious; Soft Tissue Infections | 1999 |
Comparison of sparfloxacin and ciprofloxacin in the treatment of community-acquired acute uncomplicated urinary tract infection in women. Sparfloxacin Multicenter Uncomplicated Urinary Tract Infection Study Group.
Topics: Administration, Oral; Adolescent; Adult; Anti-Infective Agents; Antitubercular Agents; Ciprofloxacin; Community-Acquired Infections; Double-Blind Method; Drug Administration Schedule; Female; Fluoroquinolones; Follow-Up Studies; Humans; Male; Middle Aged; Treatment Outcome; Urinary Tract Infections | 1999 |
196 other study(ies) available for ciprofloxacin and sparfloxacin
| Article | Year |
|---|---|
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
Topics: Alkylation; Aminoquinolines; Animals; Anti-Bacterial Agents; Bacterial Infections; Chemical Phenomena; Chemistry; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Hydroxyquinolines; Mice; Microbial Sensitivity Tests; Molecular Structure; Piperazines; Pyrrolidines; Structure-Activity Relationship; Topoisomerase II Inhibitors | 1991 |
Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.
Topics: 4-Quinolones; Animals; Anti-Infective Agents; Drug Interactions; Fluoroquinolones; Male; Mice; Microbial Sensitivity Tests; Molecular Conformation; Phenylbutyrates; Pseudomonas Infections; Rats; Streptococcal Infections; Structure-Activity Relationship; Theophylline; X-Ray Diffraction | 1990 |
The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.
Topics: Animals; Anti-Bacterial Agents; Bacteria; CHO Cells; Cricetinae; Dermatitis, Phototoxic; Drug Design; Female; Mice; Mice, Inbred Strains; Microbial Sensitivity Tests; Quinolones; Structure-Activity Relationship | 1995 |
Effect of lipophilicity at N-1 on activity of fluoroquinolones against mycobacteria.
Topics: Anti-Infective Agents; Chemical Phenomena; Chemistry, Physical; Fluoroquinolones; Kinetics; Microbial Sensitivity Tests; Mycobacterium; Piperazines; Structure-Activity Relationship | 1995 |
Structure-activity relationships of the quinolone antibacterials against mycobacteria: effect of structural changes at N-1 and C-7.
Topics: Anti-Bacterial Agents; Magnetic Resonance Spectroscopy; Microbial Sensitivity Tests; Mycobacterium; Spectrophotometry, Infrared; Structure-Activity Relationship | 1996 |
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
Topics: Blood-Brain Barrier; Databases, Factual; Models, Chemical; Molecular Conformation; Multivariate Analysis; Permeability; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
Chemometric studies on the bactericidal activity of quinolones via an extended VolSurf approach.
Topics: Anti-Bacterial Agents; Enterococcus faecalis; Escherichia coli; Models, Molecular; Pseudomonas aeruginosa; Quantitative Structure-Activity Relationship; Quinolones; Staphylococcus aureus; Thermodynamics | 2004 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Clinical Trials, Phase I as Topic; Dogs; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Half-Life; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Methicillin Resistance; Mice; Microbial Sensitivity Tests; Mutation; Prodrugs; Quinolizines; Rats; Rats, Wistar; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Structure-Activity Relationship; Vancomycin Resistance | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hybrid antibacterials. DNA polymerase-topoisomerase inhibitors.
Topics: Aniline Compounds; Animals; Anti-Bacterial Agents; DNA Polymerase III; Drug Resistance, Bacterial; Gram-Positive Bacteria; Male; Mice; Staphylococcal Infections; Staphylococcus aureus; Structure-Activity Relationship; Topoisomerase II Inhibitors; Toxicity Tests, Acute; Uracil | 2006 |
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Culture Media; Drug Resistance, Multiple, Bacterial; Enzyme Inhibitors; Indicators and Reagents; Kinetics; Microbial Sensitivity Tests; Multidrug Resistance-Associated Proteins; Norfloxacin; Omeprazole; Staphylococcus aureus; Structure-Activity Relationship | 2007 |
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Fluoroquinolones; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Predictive Value of Tests; Quinolines; Time Factors; Tuberculosis | 2007 |
Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Chemistry, Pharmaceutical; Ciprofloxacin; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Microbial Sensitivity Tests; Models, Chemical; Molecular Conformation; Pyridines; Quinolones | 2007 |
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
Topics: Anti-Infective Agents; DNA; DNA Gyrase; DNA, Superhelical; Enzyme Inhibitors; Mycobacterium leprae; Quinolones; Topoisomerase II Inhibitors | 2007 |
Tetrahydroindazole inhibitors of bacterial type II topoisomerases. Part 2: SAR development and potency against multidrug-resistant strains.
Topics: Anti-Bacterial Agents; Drug Design; Drug Resistance, Multiple; Enzyme Inhibitors; Indazoles; Microbial Sensitivity Tests; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2007 |
Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Computer Simulation; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Genes, Bacterial; Microbial Sensitivity Tests; Molecular Sequence Data; Nucleic Acid Amplification Techniques; Open Reading Frames; Plasmids; Polymerase Chain Reaction; Quinolones; Sequence Analysis, DNA; Sequence Homology, Amino Acid; Vibrio | 2007 |
Plasmid-mediated quinolone resistance determinant QnrB4 identified in France in an Enterobacter cloacae clinical isolate coexpressing a QnrS1 determinant.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Child, Preschool; Conjugation, Genetic; Drug Resistance, Bacterial; Enterobacter cloacae; Escherichia coli; France; Genes, Bacterial; Humans; Microbial Sensitivity Tests; Plasmids; Quinolones; Transformation, Genetic | 2007 |
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Chitosan; Conjugation, Genetic; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Humans; Malates; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Reverse Transcriptase Polymerase Chain Reaction; Transformation, Bacterial; Uncoupling Agents | 2007 |
Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Culture Media; DNA Gyrase; Drug Resistance, Bacterial; Enterococcus faecalis; Fluoroquinolones; Gene Expression Regulation, Bacterial; Genes, Bacterial; Microbial Sensitivity Tests; Molecular Sequence Data; Reverse Transcriptase Polymerase Chain Reaction | 2007 |
Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli.
Topics: DNA Topoisomerases; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Microbial Sensitivity Tests; Mutation | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
ISEcp1-mediated transposition of qnrB-like gene in Escherichia coli.
Topics: Base Sequence; DNA Transposable Elements; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Proteins; Microbial Sensitivity Tests; Molecular Sequence Data; Quinolones | 2008 |
Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia.
Topics: Alleles; Amino Acid Sequence; Anti-Bacterial Agents; Base Sequence; Chromosomes, Bacterial; DNA Primers; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Genes, Bacterial; Gram-Negative Bacterial Infections; Humans; Molecular Sequence Data; Sequence Homology, Amino Acid; Stenotrophomonas maltophilia | 2008 |
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
Topics: Amino Acid Substitution; Base Sequence; DNA Gyrase; DNA Mutational Analysis; DNA Primers; DNA Probes; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Genes, Bacterial; Humans; Nucleic Acid Denaturation; Point Mutation; Polymerase Chain Reaction; Streptococcus pneumoniae; Thermodynamics | 2008 |
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; Chromosome Walking; DNA-Binding Proteins; Genetic Engineering; Genome, Bacterial; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Point Mutation; Sequence Analysis, DNA; Sequence Homology, Amino Acid; Staphylococcus aureus; Vancomycin; Vancomycin Resistance | 2009 |
Targeted delivery of compounds to Trypanosoma brucei using the melamine motif.
Topics: Animals; Eflornithine; Magnetic Resonance Spectroscopy; Spectrometry, Mass, Electrospray Ionization; Triazines; Trypanocidal Agents; Trypanosoma brucei brucei | 2009 |
Emergence of quinolone-resistant Bordetella pertussis in Japan.
Topics: Anti-Bacterial Agents; Bordetella pertussis; Child; DNA Gyrase; Fluoroquinolones; Humans; Japan; Microbial Sensitivity Tests; Mutation; Nalidixic Acid; Quinolones | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Interaction of drug based binuclear mixed-ligand complexes with DNA.
Topics: Anti-Bacterial Agents; Bacteria; Binding Sites; Ciprofloxacin; Cobalt; DNA, Bacterial; Ligands; Magnetic Resonance Spectroscopy; Magnetics; Mass Spectrometry; Microbial Sensitivity Tests; Molecular Structure; Oxidation-Reduction; Spectrophotometry, Infrared; Structure-Activity Relationship; Temperature; Viscosity | 2009 |
7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Ciprofloxacin; Humans; Maximum Tolerated Dose; Mice; Neoplasms; Piperazine; Piperazines | 2009 |
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
Topics: Caco-2 Cells; Cell Membrane Permeability; Humans; Hydrogen-Ion Concentration; Membranes, Artificial; Molecular Structure; Pharmaceutical Preparations | 2010 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Cell Membrane Permeability; Cells, Cultured; Drug Resistance, Bacterial; Endosomes; Escherichia coli; Escherichia coli Infections; Female; Humans; Mice; Mice, Inbred CBA; Microbial Sensitivity Tests; Recurrence; Urinary Bladder; Urinary Tract Infections; Urothelium | 2010 |
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological; Permeability; Porosity; Regression Analysis | 2010 |
Reduced expression of the vca0421 gene of Vibrio cholerae O1 results in innate resistance to ciprofloxacin.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; Fluoroquinolones; Quinolones; Reverse Transcriptase Polymerase Chain Reaction; Vibrio cholerae O1 | 2010 |
QSAR-based solubility model for drug-like compounds.
Topics: Databases, Factual; Models, Molecular; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Solubility; Water | 2010 |
Studies on the antimicrobial properties of N-acylated ciprofloxacins.
Topics: Acylation; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Bartonella; Bartonella Infections; Ciprofloxacin; Drug Resistance, Bacterial; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Infections | 2012 |
The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel.
Topics: Anti-Bacterial Agents; Binding Sites; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluoroquinolones; Humans; Models, Molecular; Potassium Channel Blockers; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Synthesis and biological evaluation of novel structural hybrids of benzofuroxan derivatives and fluoroquinolones.
Topics: Anti-Bacterial Agents; Bacteria; Benzoxazoles; Chemistry Techniques, Synthetic; Drug Design; Fluoroquinolones; Hemolysis; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Conformation; Structure-Activity Relationship | 2016 |
Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
Topics: Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerase IV; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gram-Negative Bacteria; Gram-Positive Bacteria; HEK293 Cells; Humans; Microbial Sensitivity Tests; Molecular Structure; Quaternary Ammonium Compounds; Quinolones; Structure-Activity Relationship | 2019 |
Topoisomerase Inhibitors Addressing Fluoroquinolone Resistance in Gram-Negative Bacteria.
Topics: Anti-Bacterial Agents; Binding Sites; Cell Line, Tumor; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2020 |
Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections.
Topics: Anti-Bacterial Agents; Bacterial Infections; Carbon; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Molecular Structure; Neisseria gonorrhoeae; Structure-Activity Relationship | 2020 |
In vitro activity of sparfloxacin and three other fluoroquinolones against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Methicillin; Methicillin Resistance; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; Quinolones; Staphylococcus aureus; Staphylococcus epidermidis | 1992 |
In vitro activity of sparfloxacin (CI-978), a new broad-spectrum fluoroquinolone.
Topics: Anti-Infective Agents; Ciprofloxacin; Enterobacteriaceae; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Cocci; Microbial Sensitivity Tests; Norfloxacin; Quinolones | 1992 |
In vitro activity of sparfloxacin (AT-4140), a new quinolone agent, against invasive isolates from pediatric patients.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Humans; Infant; Infant, Newborn; Microbial Sensitivity Tests; Mutation; Quinolones | 1992 |
Antibacterial activity of sparfloxacin against experimental renal infections in mice.
Topics: Abscess; Animals; Anti-Infective Agents; Ciprofloxacin; Escherichia coli Infections; Female; Fleroxacin; Fluoroquinolones; Half-Life; Kidney Diseases; Methicillin Resistance; Mice; Quinolones; Staphylococcal Infections | 1992 |
In-vitro activity of sparfloxacin, pefloxacin, ciprofloxacin and temafloxacin against clinical isolates of Acinetobacter spp.
Topics: Acinetobacter; Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Pefloxacin; Quinolones | 1992 |
In vitro activities of five quinolones against Chlamydia pneumoniae.
Topics: Anti-Infective Agents; Chlamydophila pneumoniae; Ciprofloxacin; Fleroxacin; Fluoroquinolones; Microbial Sensitivity Tests; Ofloxacin; Quinolones | 1992 |
Absence of bactericidal activity of sparfloxacin and ciprofloxacin under anaerobic conditions.
Topics: Anaerobiosis; Anti-Infective Agents; Ciprofloxacin; Clostridium; Fluoroquinolones; Pseudomonas; Quinolones | 1992 |
Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Erythromycin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Penicillin Resistance; Quinolones; Streptococcus pneumoniae; Vancomycin; Virginiamycin | 1992 |
Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Ciprofloxacin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Quinolones | 1992 |
In vivo efficacy of a new fluoroquinolone, sparfloxacin, against penicillin-susceptible and -resistant and multiresistant strains of Streptococcus pneumoniae in a mouse model of pneumonia.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; Female; Fluoroquinolones; Leukopenia; Lung; Mice; Mice, Inbred C57BL; Penicillin Resistance; Pneumonia, Pneumococcal; Quinolones; Species Specificity; Streptococcus pneumoniae | 1992 |
In vitro and in vivo evaluation of BMY 45243, a new 5-amino-naphthyridone derivative.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Female; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Mice; Microbial Sensitivity Tests; Naphthyridines; Quinolones; Solubility | 1992 |
Activity of new quinolones against ciprofloxacin-resistant staphylococci.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Quinolones; Staphylococcus | 1991 |
Bactericidal activity of sparfloxacin and ciprofloxacin under anaerobic conditions.
Topics: Anaerobiosis; Anti-Infective Agents; Bacteroides fragilis; Ciprofloxacin; Escherichia coli; Fluoroquinolones; Microbial Sensitivity Tests; Quinolones | 1991 |
Pharmacokinetics of four fluoroquinolones in an animal model of infected lung.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; Fluoroquinolones; Lung Diseases; Mice; Mice, Inbred Strains; Ofloxacin; Pneumococcal Infections; Quinolones; Streptococcus pneumoniae | 1991 |
In vitro activity of sparfloxacin and six reference antibiotics against gram-positive bacteria.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gram-Positive Bacteria; Humans; Quinolones | 1991 |
Inhibitory effects of ciprofloxacin and sparfloxacin on DNA gyrase purified from fluoroquinolone-resistant strains of methicillin-resistant Staphylococcus aureus.
Topics: Anti-Infective Agents; Ciprofloxacin; DNA Topoisomerases, Type II; DNA, Superhelical; Drug Resistance, Microbial; Fluoroquinolones; Methicillin Resistance; Microbial Sensitivity Tests; Novobiocin; Quinolones; Staphylococcus aureus; Topoisomerase II Inhibitors | 1991 |
Mechanism of action of sparfloxacin against and mechanism of resistance in gram-negative and gram-positive bacteria.
Topics: Anti-Bacterial Agents; Ciprofloxacin; DNA Probes; DNA, Bacterial; Drug Resistance, Microbial; Enterobacteriaceae; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Mutation; Phenotype; Pseudomonas aeruginosa; Quinolones | 1991 |
In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.
Topics: Anti-Infective Agents; Bacteria; Bacteria, Anaerobic; Ciprofloxacin; Culture Media; Drug Resistance, Microbial; Fleroxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Naphthyridines | 1991 |
In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391.
Topics: Anti-Infective Agents; Ciprofloxacin; Clindamycin; Culture Media; Erythromycin; Fluoroquinolones; Hydrogen-Ion Concentration; Microbial Sensitivity Tests; Mycoplasma; Mycoplasma pneumoniae; Tetracycline; Ureaplasma | 1991 |
In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Ofloxacin | 1991 |
In vitro activity of sparfloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Enterobacteriaceae; Fluoroquinolones; Hydrogen-Ion Concentration; Microbial Sensitivity Tests; Ofloxacin | 1991 |
Interpretive criteria for disk diffusion susceptibility testing of sparfloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Regression Analysis | 1991 |
Antistaphylococcal activity of the fluoroquinolones CI-960, PD 131628, sparfloxacin, ofloxacin and ciprofloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Penicillin Resistance; Staphylococcus; Staphylococcus aureus | 1991 |
Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Naphthyridines | 1991 |
In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia.
Topics: Animals; Anti-Infective Agents; Antibodies, Bacterial; Body Weight; Ciprofloxacin; Erythromycin; Fluoroquinolones; Guinea Pigs; Half-Life; In Vitro Techniques; Legionella; Legionnaires' Disease; Lung; Macrophages; Male; Microbial Sensitivity Tests; Pulmonary Alveoli | 1990 |
In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Blood Proteins; Ciprofloxacin; Fluoroquinolones; Humans; Lactams; Microbial Sensitivity Tests; Protein Binding; Quinolones | 1990 |
In vitro susceptibility of Mycobacterium avium complex to the new fluoroquinolone sparfloxacin (CI-978; AT-4140) and comparison with ciprofloxacin.
Topics: Acquired Immunodeficiency Syndrome; Anti-Infective Agents; Ciprofloxacin; Drug Synergism; Ethambutol; Fluoroquinolones; Microbial Sensitivity Tests; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Rifampin | 1990 |
Comparative in vitro activity of the new quinolone sparfloxacin (CI-978, AT-4140) against nosocomial gram-negative bloodstream isolates.
Topics: Amikacin; Anti-Infective Agents; Cephalosporins; Ciprofloxacin; Cross Infection; Enterobacteriaceae; Fluoroquinolones; Gram-Negative Bacteria; Humans; Imipenem; Pseudomonas aeruginosa; Sepsis; Tobramycin | 1990 |
In vitro activity of sparfloxacin (CI-978; AT-4140) against clinical isolates from cancer patients.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Fleroxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Neoplasms | 1990 |
Antistaphylococcal activities of sparfloxacin (CI-978; AT-4140), ofloxacin, and ciprofloxacin.
Topics: Anti-Infective Agents; Cell Adhesion; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Hydrogen-Ion Concentration; Microbial Sensitivity Tests; Ofloxacin; Oxacillin; Plastics; Staphylococcus aureus; Staphylococcus epidermidis | 1990 |
Pharmacokinetics of a novel quinolone, AT-4140, in animals.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Bile; Ciprofloxacin; Dogs; Fluoroquinolones; Half-Life; Injections, Intravenous; Macaca fascicularis; Male; Mice; Rats; Rats, Inbred Strains; Species Specificity | 1990 |
In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Enoxacin; Fluoroquinolones; Lung Diseases; Mice; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; Skin Diseases, Infectious; Urinary Tract Infections | 1989 |
Comparison of sparfloxacin, temafloxacin, and ciprofloxacin for prophylaxis and treatment of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Foreign Bodies; Guinea Pigs; Methicillin Resistance; Microbial Sensitivity Tests; Quinolones; Rats; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 1995 |
Interactions between fluoroquinolones, Mg2+, DNA and DNA gyrase, studied by phase partitioning in an aqueous two-phase system and by affinity chromatography.
Topics: Animals; Anti-Infective Agents; Bacteria; Cattle; Chemical Phenomena; Chemistry, Physical; Chromatography, Affinity; Ciprofloxacin; Dextrans; DNA; DNA Topoisomerases, Type II; DNA, Bacterial; Escherichia coli; Fluoroquinolones; Magnesium; Polyethylene Glycols; Quinolones; Topoisomerase II Inhibitors; Water | 1994 |
A novel gyrB mutation in a fluoroquinolone-resistant clinical isolate of Salmonella typhimurium.
Topics: Anti-Infective Agents; Base Sequence; Ciprofloxacin; DNA Gyrase; DNA Topoisomerases, Type II; DNA, Bacterial; Drug Resistance, Microbial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Nalidixic Acid; Quinolones; Salmonella typhimurium | 1995 |
Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990.
Topics: Anti-Infective Agents; Bacteria; Ciprofloxacin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Naphthyridines; Quinolones | 1993 |
Intestinal elimination of sparfloxacin, fleroxacin, and ciprofloxacin in rats.
Topics: Animals; Anti-Infective Agents; Chromatography, High Pressure Liquid; Ciprofloxacin; Fleroxacin; Fluoroquinolones; Ileum; Jejunum; Male; Quinolones; Rats; Rats, Sprague-Dawley | 1995 |
Suggested modifications for disk diffusion susceptibility testing criteria for levofloxacin and sparfloxacin following tests with a predictor panel of ciprofloxacin-resistant clinical isolates.
Topics: Ciprofloxacin; Diffusion; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Reproducibility of Results | 1995 |
In-vitro postantibiotic effect of sparfloxacin and ciprofloxacin against Pseudomonas aeruginosa and Enterococcus faecalis.
Topics: Anti-Infective Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Enterococcus faecalis; Fluoroquinolones; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Quinolones; Time Factors | 1994 |
Effect of aerobic and anaerobic environments on antistaphylococcal activities of five fluoroquinolones.
Topics: Anaerobiosis; Anti-Infective Agents; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Ciprofloxacin; Fluoroquinolones; Hydrogen-Ion Concentration; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Staphylococcus aureus | 1995 |
[Bactericidal activity of ciprofloxacin and sparfloxacin. Comparison with others active antibiotics against Pasteurella multocida].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Cefpodoxime; Ceftizoxime; Ciprofloxacin; Dose-Response Relationship, Drug; Fluoroquinolones; In Vitro Techniques; Pasteurella multocida; Quinolones | 1995 |
In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Depsipeptides; Drug Resistance, Microbial; Enterococcus; Fluoroquinolones; Fusidic Acid; Microbial Sensitivity Tests; Minocycline; Naphthyridines; Novobiocin; Peptides, Cyclic; Quinolones; Teicoplanin; Vancomycin; Virginiamycin | 1995 |
Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin).
Topics: Anti-Infective Agents; Bacteria, Aerobic; Ciprofloxacin; Drug Resistance, Microbial; Drug Resistance, Multiple; Fleroxacin; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Spiro Compounds | 1995 |
Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology.
Topics: Anti-Infective Agents; Ciprofloxacin; Erythromycin; Fluoroquinolones; Kinetics; Microbial Sensitivity Tests; Penicillin G; Quinolones; Streptococcus pneumoniae; Time Factors; Vancomycin; Virginiamycin | 1994 |
Effect of newer quinolones on the extra- and intra-cellular chemiluminescence response of human polymorphonuclear leucocytes.
Topics: Anti-Infective Agents; Ciprofloxacin; Extracellular Space; Fluoroquinolones; Humans; Luminescent Measurements; Neutrophils; Ofloxacin; Quinolones; Reactive Oxygen Species; Tetradecanoylphorbol Acetate; Zymosan | 1994 |
In vitro activities of enoxacin, enrofloxacin, sparfloxacin, and ciprofloxacin against Escherichia coli strains isolated from diarrheic lambs and kids.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Diarrhea; Diarrhea, Infantile; Enoxacin; Enrofloxacin; Escherichia coli; Fluoroquinolones; Humans; Infant, Newborn; Microbial Sensitivity Tests; Quinolones; Sheep; Sheep Diseases | 1994 |
In vitro activity of subinhibitory concentrations of quinolones on urea-splitting bacteria: effect on urease activity and on cell surface hydrophobicity.
Topics: Anti-Infective Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Enterobacteriaceae; Fluoroquinolones; Norfloxacin; Ofloxacin; Proteus; Providencia; Quinolones; Surface Properties; Urea; Urease | 1995 |
In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial.
Topics: Anti-Infective Agents; Ciprofloxacin; DNA Topoisomerases, Type II; DNA, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Naphthyridines; Quinolones | 1994 |
Assessment of the bactericidal activity of sparfloxacin, ofloxacin, levofloxacin, and other fluoroquinolones compared with selected agents of proven efficacy against Listeria monocytogenes.
Topics: Ampicillin; Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Levofloxacin; Listeria monocytogenes; Listeriosis; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Trimethoprim, Sulfamethoxazole Drug Combination | 1994 |
In vitro activity of the new fluoroquinolone CP-99,219.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Naphthyridines; Quinolones | 1994 |
In-vitro activity of four new fluoroquinolones.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Quinolones | 1994 |
Increased activity of a new chlorofluoroquinolone, BAY y 3118, compared with activities of ciprofloxacin, sparfloxacin, and other antimicrobial agents against anaerobic bacteria.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Microbial Sensitivity Tests; Quinolones | 1994 |
In-vitro slime production by Staphylococcus epidermidis in presence of subinhibitory concentrations of ciprofloxacin, ofloxacin and sparfloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Staphylococcus epidermidis | 1994 |
Ciprofloxacin and sparfloxacin penetration into human brain tissue and their activity as antagonists of GABAA receptor of rat vagus nerve.
Topics: Animals; Anti-Infective Agents; Brain; Ciprofloxacin; Dose-Response Relationship, Drug; Fluoroquinolones; GABA-A Receptor Antagonists; Male; Phenylacetates; Quinolones; Rats; Rats, Sprague-Dawley; Vagus Nerve | 1994 |
Comparative in vitro activities of new quinolones against coryneform bacteria.
Topics: Anti-Infective Agents; Ciprofloxacin; Corynebacterium; Fluoroquinolones; Microbial Sensitivity Tests; Ofloxacin; Quinolones | 1994 |
Comparative activities of eight quinolones against members of the Bacteroides fragilis group.
Topics: Anti-Infective Agents; Bacteroides fragilis; Ciprofloxacin; Fluoroquinolones; Microbial Sensitivity Tests; Ofloxacin; Quinolones | 1994 |
Correlation between umuC induction and Salmonella mutagenicity assay for quinolone antimicrobial agents.
Topics: Anti-Infective Agents; Bacterial Proteins; Ciprofloxacin; DNA-Directed DNA Polymerase; Enoxacin; Escherichia coli; Escherichia coli Proteins; Fluoroquinolones; Gene Expression Regulation, Bacterial; Mutagenicity Tests; Nalidixic Acid; Naphthyridines; Norfloxacin; Quinolones; Salmonella typhimurium; SOS Response, Genetics; Species Specificity | 1993 |
[Compared antibacterial activity of a new fluoroquinolone, sparfloxacin (AT 4140, RP 64206) and four other fluoroquinolones against 332 strains of enteropathogen bacteria].
Topics: Anti-Infective Agents; Campylobacter jejuni; Ciprofloxacin; Dose-Response Relationship, Drug; Escherichia coli; Fluoroquinolones; Helicobacter pylori; Humans; In Vitro Techniques; Ofloxacin; Pefloxacin; Quinolones; Salmonella; Shigella; Vibrio cholerae; Yersinia enterocolitica | 1993 |
In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Respiratory Tract Infections | 1993 |
The in-vitro activity of Bay y 3118, a new chlorofluoroquinolone.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Chlamydia; Ciprofloxacin; Enterobacteriaceae; Fluoroquinolones; Lactams; Microbial Sensitivity Tests; Quinolones; Species Specificity; Staphylococcus | 1993 |
Antibacterial activity of NM394, the active form of prodrug NM441, a new quinolone.
Topics: Anti-Infective Agents; Bacteria; Ciprofloxacin; Dioxolanes; Enoxacin; Fluoroquinolones; Microbial Sensitivity Tests; Mutation; Naphthyridines; Ofloxacin; Piperazines; Quinolones; Topoisomerase II Inhibitors | 1993 |
Changes in adherence of respiratory pathogens to HEp-2 cells induced by subinhibitory concentrations of sparfloxacin, ciprofloxacin, and trimethoprim.
Topics: Anti-Infective Agents; Bacteria; Bacterial Adhesion; Carcinoma; Ciprofloxacin; Fluoroquinolones; Humans; Laryngeal Neoplasms; Quinolones; Respiratory Tract Infections; Trimethoprim; Tumor Cells, Cultured | 1993 |
Incomplete cross-resistance between ciprofloxacin and sparfloxacin in staphylococci, with a note on selection pressure due to clinical use of ciprofloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Methicillin Resistance; Microbial Sensitivity Tests; Phenotype; Quinolones; Staphylococcus aureus | 1993 |
In vitro activity of sparfloxacin, ciprofloxacin, ofloxacin, and other antibiotics against bloodstream isolates of gram-positive cocci.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Ofloxacin; Quinolones | 1993 |
Activities of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Microbial Sensitivity Tests; Quinolones; Streptococcus pneumoniae | 1995 |
In vitro susceptibility to ciprofloxacin of bacterial strains isolated from chronic otitis media and chronic sinusitis.
Topics: Adult; Anti-Infective Agents; Bacteria; Chronic Disease; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Ofloxacin; Otitis Media; Quinolones; Sinusitis | 1995 |
In vitro antibacterial activity of FA103, a new quinolone derivative of C-7 position with 7-perhydrodiazepinone.
Topics: Anti-Infective Agents; Azepines; Bacteria; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Humans; Norfloxacin; Ofloxacin; Quinolones | 1995 |
Activity of CP 99,219 (trovafloxacin) compared with ciprofloxacin, sparfloxacin, clinafloxacin, lomefloxacin and cefuroxime against ten penicillin-susceptible and penicillin-resistant pneumococci by time-kill methodology.
Topics: Anti-Infective Agents; Cefuroxime; Ciprofloxacin; Fluoroquinolones; Microbial Sensitivity Tests; Naphthyridines; Penicillin Resistance; Quinolones; Streptococcus pneumoniae | 1996 |
In vitro and in vivo antibacterial activities of CS-940, a new 6-fluoro-8-difluoromethoxy quinolone.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Drug Evaluation, Preclinical; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Male; Mice; Naphthyridines; Piperazines; Pneumonia, Bacterial; Quinolones | 1996 |
[Determination of antimycobacterial activities of fluoroquinolones against clinical isolates of Mycobacterium tuberculosis: comparative determination with egg-based Ogawa and agar-based Middlebrook 7H10 media].
Topics: Anti-Infective Agents; Antitubercular Agents; Ciprofloxacin; Culture Media; Fluoroquinolones; Mycobacterium tuberculosis; Norfloxacin; Ofloxacin; Quinolones | 1996 |
Effect of growth conditions on antimicrobial activity of DU-6859a and its bactericidal activity determined by the killing curve method.
Topics: Anti-Infective Agents; Cell Division; Ciprofloxacin; Culture Media; Culture Media, Serum-Free; Drug Resistance, Microbial; Escherichia coli; Fluoroquinolones; Humans; Hydrogen-Ion Concentration; Kinetics; Levofloxacin; Metals; Microbial Sensitivity Tests; Microscopy, Electron; Ofloxacin; Pseudomonas aeruginosa; Quinolones; Staphylococcus aureus; Urine | 1996 |
Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra.
Topics: Anti-Infective Agents; Antitubercular Agents; Base Sequence; Cell Wall; Cephaloridine; Ciprofloxacin; DNA Gyrase; DNA Topoisomerases, Type II; Drug Resistance, Microbial; Fluoroquinolones; Genes, Bacterial; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Norfloxacin; Ofloxacin; Permeability; Quinolones | 1996 |
In vitro activity of trovafloxacin (CP-99,219), sparfloxacin, ciprofloxacin, and fleroxacin against respiratory pathogens.
Topics: Anti-Infective Agents; Ciprofloxacin; Fleroxacin; Fluoroquinolones; Haemophilus influenzae; Humans; Microbial Sensitivity Tests; Moraxella catarrhalis; Naphthyridines; Quinolones; Respiratory Tract Infections; Streptococcus pneumoniae | 1996 |
Comparative uptake of sparfloxacin and ciprofloxacin into human THP 1 monocytic cells.
Topics: Anti-Infective Agents; Cell Line; Chromatography, High Pressure Liquid; Ciprofloxacin; Fluoroquinolones; Gemfibrozil; Humans; Hydrogen-Ion Concentration; Hypolipidemic Agents; Monocytes; Quinolones | 1996 |
Effect of paclitaxel alone or in combination on the intracellular penetration and activity of quinolones in human neutrophils.
Topics: Anti-Infective Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Ciprofloxacin; Cisplatin; Doxorubicin; Fluoroquinolones; Humans; Levofloxacin; Neutrophils; Ofloxacin; Paclitaxel; Quinolones; Staphylococcus aureus | 1996 |
Characterisation of DNA gyrase and measurement of drug accumulation in clinical isolates of Acinetobacter baumannii resistant to fluoroquinolones.
Topics: Acinetobacter; Anti-Infective Agents; Ciprofloxacin; DNA Topoisomerases, Type II; Drug Resistance, Microbial; Fluoroquinolones; Microbial Sensitivity Tests; Pefloxacin; Quinolones | 1996 |
Multicentre in-vitro evaluation of the susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis to ciprofloxacin, clarithromycin, co-amoxiclav and sparfloxacin.
Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Clarithromycin; Clavulanic Acids; Drug Evaluation; Drug Therapy, Combination; Fluoroquinolones; Haemophilus influenzae; Microbial Sensitivity Tests; Moraxella catarrhalis; Quinolones; Streptococcus pneumoniae | 1997 |
Enhanced hematopoiesis in sublethally irradiated mice treated with various quinolones.
Topics: Animals; Anti-Infective Agents; Bone Marrow; Cells, Cultured; Ciprofloxacin; Cobalt Radioisotopes; Colony-Forming Units Assay; Culture Media, Conditioned; Fleroxacin; Fluoroquinolones; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cells; Hemoglobins; Interleukin-3; Leukocyte Count; Lymphocytes; Male; Mice; Mice, Inbred BALB C; Norfloxacin; Ofloxacin; Quinolones; Whole-Body Irradiation | 1997 |
High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA.
Topics: 4-Quinolones; Anti-Infective Agents; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA Topoisomerases, Type II; Drug Resistance, Microbial; Fluoroquinolones; Genes, Bacterial; Mutation; Pefloxacin; Quinolones; Sequence Analysis, DNA; Streptococcus pneumoniae; Transformation, Genetic | 1996 |
The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bacteroides fragilis; Chlamydia; Ciprofloxacin; Clarithromycin; Doxycycline; Enterobacter; Erythromycin; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; Haemophilus influenzae; Microbial Sensitivity Tests; Naphthyridines; Piperazines; Pseudomonas aeruginosa; Quinolones; Streptococcus pneumoniae | 1997 |
In-vitro and in-vivo activities of DW-116, a new fluoroquinolone.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Dose-Response Relationship, Drug; Enterococcus faecalis; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Male; Methicillin Resistance; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Pseudomonas aeruginosa; Quinolones; Staphylococcus aureus | 1997 |
Is Escherichia coli ATCC 25922 useful for monitoring broth microdilution tests of fluoroquinolones?
Topics: Anti-Infective Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Escherichia coli; Fluoroquinolones; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Quinolones; Reproducibility of Results | 1997 |
Comparative in vitro activities of DU-6859a, levofloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against 387 aerobic and anaerobic bite wound isolates.
Topics: Animals; Anti-Infective Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Bites and Stings; Cats; Ciprofloxacin; Dogs; Fluoroquinolones; Haplorhini; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Swine; Wound Infection | 1997 |
The bactericidal activity of levofloxacin compared with ofloxacin, D-ofloxacin, ciprofloxacin, sparfloxacin and cefotaxime against Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Cefotaxime; Ciprofloxacin; Colony Count, Microbial; Fluoroquinolones; Levofloxacin; Ofloxacin; Quinolones; Streptococcus pneumoniae | 1997 |
In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Neoplasms; Norfloxacin; Ofloxacin; Quinolones | 1997 |
Time-kill study of the activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam against six anaerobes.
Topics: Anti-Infective Agents; Bacteroides; Bacteroides fragilis; Cefoxitin; Ciprofloxacin; Clostridium perfringens; Fluoroquinolones; Fusobacterium; Gram-Negative Anaerobic Bacteria; Metronidazole; Microbial Sensitivity Tests; Naphthyridines; Penicillanic Acid; Peptostreptococcus; Piperacillin; Prevotella melaninogenica; Quinolones; Tazobactam | 1997 |
In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Pefloxacin; Quinolones; Respiratory Tract Infections | 1997 |
The effects of macrolide and quinolone antibiotics in methicillin-resistant Staphylococcus aureus biofilm growth.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Biofilms; Catheterization; Ciprofloxacin; Erythromycin; Fluoroquinolones; Methicillin Resistance; Quinolones; Staphylococcus aureus | 1997 |
Comparative antistreptococcal activity of two newer fluoroquinolones, levofloxacin and sparfloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Humans; In Vitro Techniques; Levofloxacin; Ofloxacin; Pneumococcal Infections; Quinolones; Streptococcal Infections; Streptococcus; Streptococcus pneumoniae | 1997 |
In-vitro and in-vivo antibacterial activity of CFC-222, a new fluoroquinolone.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Male; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Ofloxacin; Quinolones | 1998 |
In vitro activities of six fluoroquinolones against Canadian isolates of vancomycin-sensitive and vancomycin-resistant Enterococcus species.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Canada; Ciprofloxacin; Drug Resistance, Microbial; Enterococcus; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Vancomycin | 1998 |
Pharmacodynamic activities of ciprofloxacin and sparfloxacin in a murine pneumococcal pneumonia model: relevance for drug efficacy.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Female; Fluoroquinolones; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Pneumonia, Pneumococcal; Quinolones; Streptococcus pneumoniae | 1998 |
Effects of fluoroquinolones and magnesium deficiency in murine limb bud cultures.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Embryo, Mammalian; Embryonic and Fetal Development; Extremities; Fleroxacin; Fluoroquinolones; Magnesium Deficiency; Mice; Microscopy, Electron; Ofloxacin; Pefloxacin; Quinolones | 1998 |
Uptake of fluoroquinolones in human monocytes isolated from peripheral blood.
Topics: Anti-Infective Agents; Cell Adhesion; Cell Separation; Ciprofloxacin; Flow Cytometry; Fluoroquinolones; Humans; Monocytes; Ofloxacin; Quinolones | 1998 |
Antimicrobial activity of gatifloxacin tested against 1676 strains of ciprofloxacin-resistant gram-positive cocci isolated from patient infections in North and South America.
Topics: Anti-Infective Agents; Antitubercular Agents; Bacteriological Techniques; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests; Naphthyridines; North America; Quinolones; South America | 1998 |
Antistaphylococcal and antistreptococcal killing kinetics of ciprofloxacin, ofloxacin, sparfloxacin, and trovafloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Quinolones; Staphylococcal Infections; Staphylococcus aureus; Streptococcal Infections; Streptococcus pneumoniae; Streptococcus pyogenes | 1998 |
Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-re
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gentamicins; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Quinolones; Staphylococcus aureus; Vancomycin; Virginiamycin | 1999 |
[Relationship between the sensitivity of Pseudomonas aeruginosa and the post-antibiotic effect of sparfloxacin and ciprofloxacin].
Topics: Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Fluoroquinolones; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 1998 |
The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Genes, Bacterial; Humans; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Polymerase Chain Reaction; Quinolines; Reserpine; Staphylococcal Infections; Staphylococcus aureus | 1998 |
[In vitro activity of fluoroquinolones and oral beta lactam antibiotics against clinical isolates of Escherichia coli].
Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactams; Ciprofloxacin; Escherichia coli; Fluoroquinolones; Humans; Microbial Sensitivity Tests | 1999 |
The bactericidal activity of levofloxacin against ampicillin-resistant and ampicillin-susceptible Haemophilus influenzae in comparison with ofloxacin, ciprofloxacin and sparfloxacin.
Topics: Ampicillin; Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Haemophilus influenzae; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin | 1999 |
Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones.
Topics: Anti-Infective Agents; Ciprofloxacin; DNA Topoisomerase IV; DNA Topoisomerases, Type II; Escherichia coli; Fluoroquinolones; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Enzymologic; Genes, Bacterial; Streptococcus pneumoniae | 1999 |
Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents.
Topics: Amoxicillin; Anti-Infective Agents; Ceftriaxone; Cefuroxime; Cephalosporins; Ciprofloxacin; Clarithromycin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Penicillin Resistance; Streptococcus pneumoniae | 1999 |
In-vitro activity of grepafloxacin, a new fluoroquinolone, against mycoplasmas.
Topics: Anti-Infective Agents; Ciprofloxacin; Doxycycline; Erythromycin; Fluoroquinolones; Microbial Sensitivity Tests; Mycoplasma; Ofloxacin; Piperazines; Ureaplasma urealyticum | 1999 |
In-vitro bacteriostatic activity of levofloxacin and three other fluoroquinolones against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Penicillin Resistance; Streptococcus pneumoniae | 1999 |
In-vitro activity of levofloxacin, a new fluoroquinolone: evaluation against Haemophilus influenzae and Moraxella catarrhalis.
Topics: Anti-Infective Agents; beta-Lactamases; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Ofloxacin; Pefloxacin | 1999 |
Relative potential for selection of fluoroquinolone-resistant Streptococcus pneumoniae strains by levofloxacin: comparison with ciprofloxacin, sparfloxacin and ofloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Streptococcus pneumoniae | 1999 |
Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
Topics: Adrenergic Uptake Inhibitors; Anti-Infective Agents; Antitubercular Agents; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA Topoisomerases, Type II; DNA, Bacterial; DNA, Superhelical; Drug Interactions; Drug Resistance, Microbial; Enzyme Inhibitors; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Mutation; Naphthyridines; Ofloxacin; Reserpine; Staphylococcus aureus; Topoisomerase II Inhibitors | 1999 |
Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones.
Topics: Anti-Infective Agents; Antitubercular Agents; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA Topoisomerases, Type II; DNA, Bacterial; Drug Resistance, Microbial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Mutation; Naphthyridines; Ofloxacin; Phenotype; Streptococcus pneumoniae; Transformation, Bacterial | 1999 |
Will pneumococci put quinolones in their place?
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Ofloxacin; Streptococcus pneumoniae | 1999 |
[Community-acquired respiratory tract infections. Current data on the efficacy of various classes of antibiotics and antibiotic resistance of the main prevalent bacteria species].
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Community-Acquired Infections; Drug Resistance, Microbial; Erythromycin; Female; Fluoroquinolones; Germany; Haemophilus influenzae; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moraxella catarrhalis; Population Surveillance; Respiratory Tract Infections; Sampling Studies; Streptococcus pneumoniae; Tetracycline | 1999 |
Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
Topics: 4-Quinolones; Aminopyridines; Anti-Infective Agents; Antitubercular Agents; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Mycobacterium avium Complex; Mycobacterium tuberculosis; Ofloxacin; Quinolones; Rifamycins | 2000 |
Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model.
Topics: Anti-Infective Agents; Blood Coagulation; Ciprofloxacin; Fibrin; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Penicillin Resistance; Pneumococcal Infections; Streptococcus pneumoniae | 2000 |
Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Bacteremia; Ciprofloxacin; Fluoroquinolones; Gemifloxacin; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines | 2000 |
Action of quinolones against Staphylococcus aureus topoisomerase IV: basis for DNA cleavage enhancement.
Topics: Anti-Infective Agents; Catalysis; Ciprofloxacin; DNA; DNA Topoisomerase IV; DNA Topoisomerases, Type II; Drug Resistance, Microbial; Fluoroquinolones; Levofloxacin; Naphthyridines; Ofloxacin; Staphylococcus aureus; Topoisomerase II Inhibitors | 2000 |
New classification and update on the quinolone antibiotics.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Humans; Naphthyridines | 2000 |
In vitro activity of trovafloxacin compared to those of five antimicrobials against mycoplasmas including Mycoplasma hominis and Ureaplasma urealyticum fluoroquinolone-resistant isolates that have been genetically characterized.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Doxycycline; Drug Resistance, Microbial; Erythromycin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mycoplasma hominis; Naphthyridines; Ofloxacin; Ureaplasma urealyticum | 2000 |
Antimicrobial activity of gemifloxacin (SB-265805), a newer fluoroquinolone, against clinical isolates of Neisseria gonorrhoeae, including fluoroquinolone-resistant isolates.
Topics: Amoxicillin; Anti-Infective Agents; Ciprofloxacin; Clavulanic Acid; Drug Resistance, Microbial; Fluoroquinolones; Gemifloxacin; Gonorrhea; Humans; Levofloxacin; Naphthyridines; Neisseria gonorrhoeae; Norfloxacin; Ofloxacin | 2000 |
Effects of sparfloxacin, grepafloxacin, moxifloxacin, and ciprofloxacin on cardiac action potential duration.
Topics: Action Potentials; Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Dogs; Female; Fluoroquinolones; Heart; Male; Moxifloxacin; Piperazines; Quinolines; Time Factors | 2000 |
Bactericidal assays for fluoroquinolones.
Topics: Anti-Infective Agents; Ciprofloxacin; DNA Topoisomerases, Type II; DNA, Superhelical; Escherichia coli; Fluoroquinolones; Kinetics; Microbial Sensitivity Tests; Naphthyridines; Nephelometry and Turbidimetry; Plasmids; Quality Control; Topoisomerase II Inhibitors | 2001 |
In vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin.
Topics: 4-Quinolones; Animals; Anti-Infective Agents; Antitubercular Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Brain; Cell Line; Ciprofloxacin; Fleroxacin; Fluoroquinolones; Infusions, Intra-Arterial; Kidney; Mice; Mice, Inbred Strains; Mice, Knockout; Microdialysis; Norfloxacin; Pefloxacin; Recombinant Proteins; Rhodamine 123; Swine; Tissue Distribution; Transfection | 2000 |
[The frequency of Streptococcus pneumoniae strains and sensitivity surveillance for several antibiotics in Gifu Prefecture].
Topics: Amoxicillin; Anti-Bacterial Agents; Cefaclor; Cefdinir; Cefixime; Cefmenoxime; Cefpodoxime; Ceftizoxime; Cephalosporins; Ciprofloxacin; Clarithromycin; Clindamycin; Drug Resistance, Microbial; Fluoroquinolones; Humans; Imipenem; Japan; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Minocycline; Naphthyridines; Ofloxacin; Penicillin G; Penicillins; Streptococcus pneumoniae; Thienamycins | 2000 |
A comparison of the bactericidal activity of quinolone antibiotics in a Mycobacterium fortuitum model.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Mycobacterium fortuitum; Mycobacterium Infections, Nontuberculous; Ofloxacin; Quinolines | 2001 |
[Comparison of in vitro antimicrobial activities of ofloxacin, levofloxacin, ciprofloxacin, and sparfloxacin against various mycobacteria].
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Levofloxacin; Mycobacterium; Mycobacterium fortuitum; Mycobacterium kansasii; Mycobacterium tuberculosis; Ofloxacin | 2001 |
The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence of resistance.
Topics: Anti-Infective Agents; Area Under Curve; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Streptococcus pneumoniae | 2001 |
Comparison of the in vitro activities of BMS-284756 and four fluoroquinolones against Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Fluoroquinolones; Humans; Indoles; Microbial Sensitivity Tests; Moxifloxacin; Norfloxacin; Quinolines; Quinolones; Streptococcus pneumoniae | 2001 |
Elimination of mycoplasma from leukemia-lymphoma cell lines using antibiotics.
Topics: Algorithms; Anti-Bacterial Agents; Anti-Infective Agents; Cell Culture Techniques; Ciprofloxacin; Culture Media; Diterpenes; Drug Resistance; Drug Resistance, Multiple, Bacterial; Enrofloxacin; Fluoroquinolones; Humans; Leukemia; Lymphoma; Minocycline; Mycoplasma; Quinolones; Suspensions; Tumor Cells, Cultured | 2002 |
Minimal inhibitory concentrations and time-kill determination of moxifloxacin against aerobic and anaerobic isolates.
Topics: Aerobiosis; Anaerobiosis; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Bacteria; Ceftriaxone; Cephalosporins; Ciprofloxacin; Clindamycin; Clostridium; Drug Resistance, Multiple, Bacterial; Erythromycin; Fluoroquinolones; Imipenem; Microbial Sensitivity Tests; Moxifloxacin; Mycoplasma; Quinolines; Streptococcus; Teicoplanin; Thienamycins; Vancomycin | 2002 |
[Phototoxicity studies of pazufloxacin mesilate, a novel parenteral quinolone antimicrobial agent--in vitro and in vivo studies].
Topics: Animals; Anti-Infective Agents; Cells, Cultured; Ciprofloxacin; Dermatitis, Phototoxic; Enoxacin; Female; Fluoroquinolones; Guinea Pigs; Nalidixic Acid; Ofloxacin; Oxazines; Quinolones; Rats; Rats, Sprague-Dawley; Ultraviolet Rays | 2002 |
[Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate, a new quinolone antibacterial agent for intravenous use: convulsions in mice after intravenous or intracerebroventricular administration].
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; beta-Alanine; Biphenyl Compounds; Cefazolin; Cilastatin; Cilastatin, Imipenem Drug Combination; Ciprofloxacin; Convulsants; Drug Combinations; Drug Interactions; Enoxacin; Fleroxacin; Fluoroquinolones; Imipenem; Injections, Intravenous; Injections, Intraventricular; Male; Mice; Mice, Inbred ICR; Norfloxacin; Oxazines; Penicillin G; Quinolones; Seizures; Thienamycins | 2002 |
[Comparative in vitro activities of several antimicrobial agents against Helicobacter pylori].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Ciprofloxacin; Clarithromycin; Drug Resistance, Bacterial; Erythromycin; Fluoroquinolones; Gastric Mucosa; Helicobacter pylori; Humans; Levofloxacin; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; Penicillins; Stomach Ulcer | 2002 |
Transintestinal secretion of ciprofloxacin, grepafloxacin and sparfloxacin: in vitro and in situ inhibition studies.
Topics: Animals; Anti-Infective Agents; Biological Availability; Caco-2 Cells; Chromatography, High Pressure Liquid; Ciprofloxacin; Drug Carriers; Fluoroquinolones; Humans; In Vitro Techniques; Intestinal Absorption; Male; Models, Biological; Piperazines; Rats; Rats, Wistar | 2003 |
Reliability of phototoxic tests of fluoroquinolones in vitro.
Topics: 3T3 Cells; Animals; Anti-Infective Agents; Ciprofloxacin; Cricetinae; Cricetulus; Dermatitis, Phototoxic; Female; Fluoroquinolones; Mice; Mice, Inbred BALB C; Micronucleus Tests; Norfloxacin; Quinolones; Rats; Rats, Wistar; Ultraviolet Rays | 2003 |
Binding characteristics of fluoroquinolones to synthetic levodopa melanin.
Topics: Binding Sites; Chloroquine; Ciprofloxacin; Drug Interactions; Enoxacin; Fluoroquinolones; Levodopa; Levofloxacin; Melanins; Monophenol Monooxygenase; Norfloxacin; Ofloxacin; Quinolones; Timolol | 2003 |
Efficacy of amikacin combinations for nocardiosis.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; beta-Lactams; Cefotaxime; Ciprofloxacin; DNA, Ribosomal; Drug Therapy, Combination; Erythromycin; Female; Fluoroquinolones; Gram-Positive Bacteria; Humans; Imipenem; Lactams; Male; Middle Aged; Minocycline; Nocardia; Nocardia Infections; RNA, Ribosomal, 16S; Streptomyces; Sulfamethoxazole; Trimethoprim | 2003 |
Compare two methods of measuring DNA damage induced by photogenotoxicity of fluoroquinolones.
Topics: Animals; Anti-Infective Agents; Cells, Cultured; Ciprofloxacin; Comet Assay; Cricetinae; Cricetulus; DNA; DNA Damage; Fibroblasts; Fluoroquinolones; Levofloxacin; Ofloxacin; Quinolones; Ultraviolet Rays | 2004 |
[Study on the gene mutation of quinolone-resistant Mycobacterium tuberculosis isolated from Sichuan Province].
Topics: Antibiotics, Antitubercular; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Mutation; Mycobacterium tuberculosis; Ofloxacin; Polymorphism, Single-Stranded Conformational; Quinolones | 2004 |
Simultaneous determination of trace of loxacin, ciprofloxacin, and sparfloxacin by micelle TLC-fluorimetry.
Topics: Anti-Bacterial Agents; Calibration; Chromatography, Thin Layer; Ciprofloxacin; Fluorometry; Fluoroquinolones; Micelles; Ofloxacin | 2004 |
In vitro activity of fluoroquinolones against Mycobacterium tuberculosis.
Topics: Aza Compounds; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Quinolones; Sampling Studies; Sensitivity and Specificity | 2005 |
A fluoroquinolone resistance protein from Mycobacterium tuberculosis that mimics DNA.
Topics: Amino Acid Sequence; Antitubercular Agents; Bacterial Proteins; Ciprofloxacin; Crystallography, X-Ray; DNA Gyrase; DNA, Bacterial; DNA, Superhelical; Drug Resistance, Bacterial; Drug Resistance, Microbial; Enzyme Inhibitors; Escherichia coli; Fluoroquinolones; Models, Molecular; Molecular Mimicry; Molecular Sequence Data; Monomeric GTP-Binding Proteins; Mycobacterium tuberculosis; Protein Conformation; Protein Folding; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2005 |
[Determination of 16 quinolone residues in animal tissues using high performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry].
Topics: Animals; Chromatography, High Pressure Liquid; Ciprofloxacin; Enoxacin; Enrofloxacin; Fluoroquinolones; Norfloxacin; Ofloxacin; Pefloxacin; Quinolones; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization | 2007 |
[Genetical conditioning of fluoroquinolone resistance mechanisms of clinical enterococcus faecalis strains. II. The mutations present in the qrdrs of gyrA, gyrB, parC and parE genes].
Topics: Amino Acid Substitution; Aza Compounds; Bacterial Proteins; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Bacterial; Enterococcus faecalis; Fluoroquinolones; Genes, Bacterial; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Polymerase Chain Reaction; Quinolines; Species Specificity | 2007 |
Novel gyrase mutations and characterization of ciprofloxacin-resistant clinical strains of Enterococcus faecalis isolated in Poland.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Bacterial; Enterococcus faecalis; Fluoroquinolones; Genes, Bacterial; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Poland; Polymerase Chain Reaction; Quinolines; Sequence Analysis, DNA | 2008 |
Quantitative comparison of the convulsive activity of combinations of twelve fluoroquinolones with five nonsteroidal antiinflammatory agents.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Ciprofloxacin; Diclofenac; Dioxolanes; Drug Combinations; Drug Interactions; Enoxacin; Fleroxacin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Male; Mice; Microbial Sensitivity Tests; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Phenylacetates; Piperazines; Receptors, GABA-A; Seizures | 2009 |
A comparative analysis of chromosomal aberrations in cultured human lymphocytes due to fluoroquinolone drugs at different expression periods.
Topics: Anti-Infective Agents; Cell Cycle; Cells, Cultured; Chromosome Aberrations; Ciprofloxacin; DNA Replication; Dose-Response Relationship, Drug; Fluoroquinolones; Gatifloxacin; Humans; Lymphocytes; Ofloxacin | 2010 |
Bacteriological agents of chronic discharging ears and their antibiotic sensitivity pattern in Ido - Ekiti, Nigeria.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftriaxone; Cefuroxime; Child; Child, Preschool; Ciprofloxacin; Drug Resistance, Bacterial; Enterobacteriaceae; Female; Fluoroquinolones; Gram-Negative Bacterial Infections; Humans; Infant; Klebsiella; Male; Microbial Sensitivity Tests; Middle Aged; Nigeria; Otitis Media, Suppurative; Prospective Studies; Proteus; Pseudomonas; Staphylococcus aureus; Young Adult | 2012 |
Experimental and theoretical studies on the molecular properties of ciprofloxacin, norfloxacin, pefloxacin, sparfloxacin, and gatifloxacin in determining bioavailability.
Topics: Biological Availability; Buffers; Ciprofloxacin; Fluoroquinolones; Gastrointestinal Absorption; Gatifloxacin; Hydrogen-Ion Concentration; Models, Molecular; Molecular Conformation; Norfloxacin; Octanols; Pefloxacin; Phosphates; Solvents; Static Electricity; Thermodynamics | 2014 |
Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates.
Topics: Aminopyridines; Antitubercular Agents; Ciprofloxacin; DNA Gyrase; Drug Resistance, Bacterial; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Gatifloxacin; Gene Expression; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Thailand; Tuberculosis, Pulmonary | 2016 |
Three new platinum complexes containing fluoroquinolones and DMSO: Cytotoxicity and evaluation against drug-resistant tuberculosis.
Topics: Cell Line, Tumor; Cell Survival; Ciprofloxacin; Dimethyl Sulfoxide; Drug Screening Assays, Antitumor; Fluoroquinolones; Humans; MCF-7 Cells; Mycobacterium tuberculosis; Ofloxacin; Tuberculosis, Multidrug-Resistant | 2018 |